Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - Purchase, NY – August 8, 2024 – Cognition The ...

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...

Core Viewpoint - Cognition Therapeutics, Inc. is set to release its financial results for Q2 2024 on August 8, 2024, and will host a conference call to discuss these results and provide a business update [1]. Group 1: Financial Results Announcement - The financial results for the second quarter ended June 30, 2024, will be released before the market opens on August 8, 2024 [1]. - A conference call will take place at 8:30 a.m. ET on the same day to review the financial and operating results [1]. Group 2: Conference Call Details - The conference call can be accessed via a toll-free number for US/Canada participants: (800) 715-9871, and an international dial-in number: (646) 307-1963 [2]. - The conference ID number for the call is 3702003 [2]. - An audio webcast with live Q&A will be available, and an archive of the webcast will be accessible for 90 days starting at approximately 10:30 a.m. ET on August 8, 2024 [2]. Group 3: Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [3]. - The company is investigating its lead candidate CT1812 in clinical programs for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration [3]. - CT1812 targets the σ-2 receptor, representing a distinct mechanism compared to other current treatment approaches for degenerative diseases [3].

Cognition Therapeutics (NASDAQ:CGTX) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 'SHINE' study. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. More Monday Stock Market News What's Next for CGTX Stock Thi ...

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - "The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements ...

Core Insights - Cognition Therapeutics, Inc. reported positive results from the Phase 2 'SHINE' study of CT1812, showing cognitive improvement in participants treated for six months compared to placebo across various cognitive measures [1][9][12] - The study demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events being mild or moderate [10][12][18] - CT1812 showed significant changes in neurofilament light chain, a marker of neurodegeneration, particularly at the 300mg dose [2][12] Study Details - The SHINE study enrolled 153 adults with mild-to-moderate Alzheimer's disease, randomized to receive either placebo or one of two doses of CT1812 (100mg or 300mg) [18][22] - The primary endpoint was safety and tolerability, while the key secondary endpoint focused on cognitive measures, specifically ADAS-Cog 11 [22] - Participants in the placebo arm experienced a decline of approximately 2.70 points on ADAS-Cog 11, while those treated with CT1812 declined by an average of 1.66 points, indicating a 39% slowing of decline [18][22] Clinical Implications - The results suggest that CT1812 may serve as a monotherapy or in combination with approved drugs for treating Alzheimer's disease and related dementias [9][12] - The findings from the SHINE study will inform future clinical trials and dose selection for CT1812 [9][12][12] - The company is also conducting additional studies, including the SHIMMER trial for Lewy body dementia and the START trial for early-stage Alzheimer's disease [11][23] Safety Profile - The overall percentage of participants experiencing any adverse event was similar between CT1812 treatment arms (76.5%) and the placebo group (78%) [10][12] - Serious adverse events were reported in 6% of CT1812-treated participants compared to 10% in the placebo group [19] - Treatment-emergent liver function test (LFT) increases were observed in the 300mg group but subsided after drug cessation without serious liver injury [3][10] Future Outlook - The company is optimistic about the SHINE results and anticipates further insights from ongoing trials [11][12] - Cognition Therapeutics has received over $170 million in grant support from various institutions, aiding its research and development efforts [11] - The company aims to advance CT1812 in clinical trials targeting neurodegenerative diseases, leveraging the distinct mechanism of action of the σ-2 receptor [24]

The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant ...

Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday. AAIC Presentation details 1. Abstract #95147: CSF Phosphoproteomics Biomarker An ...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, ...

Core Insights - Cognition Therapeutics, Inc. announced that abstracts from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for presentation at the Alzheimer's Association's International Conference in Philadelphia from July 28-August 1, 2024 [1][2] Study Details - The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial enrolling approximately 144 patients with mild-to-moderate Alzheimer's disease, with participants randomized to receive either placebo or CT1812 at doses of 100 mg or 300 mg daily for six months [3] - The study endpoints include safety, cognitive function measured by the ADAS-Cog 11 scale, and biomarker evidence of disease modification, supported by approximately $30 million in grants from the National Institute on Aging [3] Drug Information - CT1812 is an experimental orally delivered small molecule that selectively binds to the sigma-2 receptor complex, displacing toxic Aβ oligomers, which are implicated in Alzheimer's disease progression [4] - The sigma-2 receptor complex is involved in regulating cellular processes that are damaged by toxic interactions with Aβ oligomers and oxidative stress, leading to cognitive impairment [4] Ongoing Studies - The company is currently recruiting participants for the START study of CT1812 in early Alzheimer's disease and the MAGNIFY study in adults with geographic atrophy due to dry age-related macular degeneration [5] - Enrollment has completed in the SHIMMER study of CT1812 in adults with dementia with Lewy bodies and the SHINE study [5] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [6] - The company is investigating CT1812 in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration, with a belief that targeting the sigma-2 receptor represents a distinct mechanism from other current treatment approaches [6]